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A randomized trial of minidose warfarin for the prevention of being dialyzed using a tunneled cuffed catheter (TCC)
late malfunction in tunneled, cuffed hemodialysis catheters. within the first 60 days of HD initiation, and 13% of
Background. Minidose warfarin (1 mg/day) has been associ- patients were using a TCC after this period [1]. Theated with a 74% reduction in the thrombosis rate of central
estimated one-year patency rate of TCCs is in the rangevenous catheters used in oncology patients. To determine the
efficacy of minidose warfarin on late malfunction caused by of 30 to 74% [2–6]. Early TCC malfunction (,2 weeks)
thrombosis or fibrin sheath formation in tunneled, cuffed cathe- occurs in 1 to 9% of cases and is most often due to a
ters (TCC) used for hemodialysis (HD), we performed a ran- mechanical problem such as improper tip position ordomized, placebo-controlled trial.
catheter kinking [4, 5]. Late TCC malfunction (.2Methods. One hundred five chronic HD patients with TCCs
weeks) is caused by TCC thrombosis or fibrin sheathwere initially randomized. Of these, 85 (warfarin 41 and pla-
cebo 44) completed the first two weeks of the protocol and formation in 98% of the cases [4, 5]. Failure to maintain
were followed for the first year of TCC life or until TCC an adequate TCC blood flow threatens HD adequacy,removal.
and the treatment of TCC malfunction is expensive, andResults. Sixteen TCCs failed with late TCC malfunction, eight
oftentimes invasive, contributing to HD cost and ex-in each group. In a multivariate analysis, there was no signifi-
cant effect of warfarin on thrombosis-free TCC survival or time posing patients to procedural risks [7, 8].
to the first urokinase (UK) instillation for incipient thrombosis. Minidose warfarin (1 mg daily) has been shown to beThe presence of a low hemoglobin (Hgb; ,10.5 g/dL) or a low
effective in reducing central vein catheter thrombosisinternational normalized ratio (INR; ,1.00) was significantly
rates by 74% in cancer patients [9]. Low-intensity warfa-associated with a higher risk of late TCC malfunction (RR 5.2
and 4.0, respectively), a higher risk of incipient TCC thrombosis rin regimens have also been used for thrombosis prophy-
requiring UK (RR 2.0 and 2.8, respectively), and higher rates laxis in patients undergoing surgical procedures and in
of UK dosing. Diabetics had a 3.6-fold higher risk of late TCC
patients with metastatic cancer [10, 11]. The advantagesmalfunction and a twofold higher risk of incipient thrombosis
of fixed-dose minidose warfarin are the relatively lowrequiring UK, although these findings were not statistically
significant. Aspirin use, race, age, number of hospitalizations, bleeding risk and the fact that frequent laboratory moni-
erythropoietin dose, intradialytic heparin dose, serum albumin, toring is not required [12]. In fact, the prothrombin time
and the number of episodes of TCC-associated infection were
(PT), and levels of antithrombin III, factors II, VII, IX,not significantly associated with late TCC malfunction.
X, Xa inhibitor, and prothrombin fragments 1 and 2Conclusions. Thrombosis prophylaxis using fixed minidose
warfarin is not efficacious in TCCs used for HD. However, the are not detectably altered at this low dose, although at
present data suggest improved TCC survival in patients with slightly higher doses (1.25 mg/day), a significant increase
an INR .1.00. Patients with diabetes and those with a low
in the international normalized ratio (INR) of the PT hasHgb or INR have a higher risk of late TCC malfunction.
been reported [9, 13]. The mechanism whereby minidose
warfarin reduces the propensity toward thrombosis is
unknown, although the presence of an in vivo effect onData from the 1996 United States Renal Data System
the vitamin K-dependent factors that is undetectable byreported that 19% of hemodialysis (HD) patients were
ex vivo functional assays has been hypothesized [9].
To date, no such trials have been performed in TCCsKey words: tunneled cuffed catheters, thrombosis, chronic renal dis-
ease, dialysis access, fibrin sheath formation. used for HD, and clear guidelines for the use of minidose
warfarin for TCCs are lacking in the Dialysis OutcomesReceived for publication September 20, 2000
Quality Initiative (DOQI) [8]. To determine the efficacyand in revised form November 30, 2000
Accepted for publication December 4, 2000 of minidose warfarin as a means of preventing late TCC
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mation in TCCs used for HD, a randomized placebo- TCC function using low-dose UK was managed by ad-
ministering high-dose UK (125,000 U/5 mL) into eachcontrolled trial was performed.
TCC port for at least one hour or by proceeding to a
fibrin sheath stripping procedure (performed by inter-
METHODS
ventional radiology) or TCC replacement.
All patients were recruited from May 1997 to Septem- The following patient demographic data were re-
ber 1999. Three centers, affiliates with the Albert Ein- corded at the time of randomization: age, sex, race, etiol-
stein College of Medicine, participated: Jacobi Medical ogy of end-stage renal disease, the presence of diabetes
Center and both divisions of Montefiore Medical Center, mellitus, daily aspirin use or other antiplatelet therapy,
Weiler Hospital and the Moses Division. After initiation and a history of malignancy and/or previous venous
of HD in the hospital-based unit, all patients received thromboses. Laboratory data obtained at baseline in-
chronic HD in one of four free-standing units. Patients cluded a complete blood count (CBC), prothrombin time
were recruited within three days of TCC insertion, and (PT), partial thromboplastin time (PTT), and INR.
only patients receiving their first TCC were eligible to To avoid misclassification of mechanical TCC mal-
participate. Patients were excluded if they were receiving function as a thrombosis, only patients who successfully
systemic anticoagulation, if there was an existing contra- completed the first two weeks of the protocol, with satis-
indication to warfarin therapy, or if they refused to con- factory function of their TCC, were included. After this
sent. Randomization was centralized and was performed two-week period, an intention to treat policy was imple-
independent of aspirin use. Coumadint (warfarin) 1 mg mented. Monthly pill counts were performed to monitor
was provided by DuPont Pharmaceuticals (Wilmington, patient compliance.
DE, USA). The Jacobi Medical Center pharmacy re- During the study period, weekly laboratory data in-
packaged the active drug and provided similar placebo cluded a CBC, PT, PTT, and INR. The HD staff was
capsules to facilitate a double-blinded study design. instructed to obtain blood samples using a “heparin
All catheters were tunneled, cuffed, dual-lumen, silas- washout” technique: After discarding the intracatheter
tic catheters used only for HD (Quinton PermCathe; heparin, an additional 10 mL of blood were withdrawn
Quinton Instrument Company, Bothell, WA, USA; Med- before drawing the sample sent for analysis. Monthly
comp Hemo-cathe; Medical Components Inc., Harlys- data collection included a midweek urea reduction ratio
ville, PA, USA; and the Bard Vas-cathe; Bard Access (URR) and serum albumin. Data regarding the mean
Systems, Inc, Salt Lake City, UT, USA). Standard cathe- TCC BFR per week, date of TCC insertion and removal,
ter care during this period consisted of cleansing the and the reason for TCC removal were recorded. The
catheter exit site with povidone-iodine solution alone mean intradialytic heparin dose, erythropoietin dose,
or povidone-iodine followed by isopropyl alcohol, and and the number of hospitalizations were documented.
covered with a transparent, oxygen permeable dressing Quantitative and qualitative data about TCC-related in-
(OpSitee Smith and Nephew Ltd., Largo, CA, USA) fections and adverse events were monitored. Late TCC
with or without gauze. Catheter dressings were changed malfunction was defined as the presence of an inade-
three times weekly by the HD staff. The HD prescription quate TCC BFR, without evidence of a mechanical mal-
and intradialytic heparinization protocol were individu- function by chest radiograph and/or venography, after a
alized for each patient and were determined by the pa- previously successful period of TCC function (.2
tient’s physician. The minimum TCC blood flow rate weeks). The primary endpoint of the study was the days
(BFR) prescribed was 300 mL/min, and heparin (5000 of thrombosis-free TCC survival until TCC failure and
U/mL) was instilled into both lumens of the TCC after removal because of late malfunction. The secondary end-
each treatment by the HD staff. BFRs were recorded points were (1) the number of days to first intervention
throughout the HD procedure three times weekly. When with UK for incipient thrombosis and (2) the rate of UK
incipient TCC thrombosis was suspected, an attempt was dosing. After June 1999, because of the removal of UK
made at TCC thrombolysis using low-dose urokinase from clinical use, a surrogate marker for incipient throm-
(UK; 5000 U/mL). Incipient thrombosis was defined as bosis was utilized: mean TCC BFR of less than 200 mL/
difficulty aspirating blood from the TCC lumen or a min recorded during two consecutive treatments. The
mean TCC BFR of less than 200 mL/min during HD for number of fibrin sheath stripping procedures was re-
two consecutive treatments despite repositioning of the corded. The follow-up period was a maximum of one
patient. These criteria were determined a priori by the year of TCC survival or until the TCC was removed.
investigators prior to the publication of the DOQI guide- A prospective construction of sample size based on
lines, which recommend that a BFR of ,300 mL/min be an effect size of 50% was performed using an a of 0.05
used to define TCC malfunction [8]. UK was adminis- and 80% power. This analysis indicated that 42 patients
tered into the fill volume (1 to 1.5 mL) of each TCC per arm were needed. Bern et al reported a 75% reduc-
tion in venogram-proven thrombosis in oncology patientslumen for a minimum of 30 minutes. Failure to improve
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Fig. 1. Patient identification and randomization.
with central vein catheters receiving minidose warfarin the full study protocol. Twenty patients (11 W and 9 P)
were removed from the protocol prior to the first two[9]. Independent t tests were used to analyze differences
weeks, and the reasons for withdrawal are provided inin continuous outcome variables between groups, whereas
Figure 1. TCC type was as follows: 70 Quinton Permcathspaired t tests were used to analyze repeat measurements
(34 W and 36 P), 13 Medcomp catheters (6 W and 7 P),of continuous variables in the same group. All tests were
and 2 Bard catheters (2 P). The site of TCC insertiontwo-sided a 5 0.05. Chi square was used to analyze
was as follows: 75 right internal jugular vein (33 W andcategorical variables. Linear regression was performed
42 P), 4 left internal jugular vein (3 W and 1 P), and 6to determine factors associated with the rate of UK dos-
subclavian vein (4 W and 2 P). Table 1 provides dataing. Logistic regression was used to determine which
regarding patient demographics, baseline laboratory val-variables correlated with the serum hemoglobin values
ues, and the renal diagnoses for all 85 patients. Out of(dichotomized). The length of time to events were ana-
19 patients who were still active in the protocol afterlyzed using both Kaplan–Meier test (log-rank test) and
June 1999 (after which UK was unavailable), only 4 hadfor multivariate analysis, the Cox proportional hazards
an indication for UK, as defined as a TCC BFR of 200test. Plus-minus signs indicate means 6 SEM. The analy-
mL/min for two consecutive treatments.ses were performed using SPSS software.
With regard to baseline laboratory values and demo-
graphics, the groups were comparable, except for the
RESULTS presence of a higher mean baseline hemoglobin in the
Of 112 patients identified, 105 consented to partici- placebo group (Table 1). A similar percentage of patients
pate, were randomized, and started the study drug: 52 was receiving aspirin in each group, and none were re-
warfarin (W) and 53 placebo (P) (Fig. 1). Of these, 85 ceiving other antiplatelet agents on a daily basis. Compli-
patients (41 W and 44 P) had a successfully functioning ance with study medication was similar (89% W and 91%
P). During the study period, there were no differences inTCC after the initial two-week period and completed
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Table 3. Reasons for protocol completionTable 1. Patient demographics and baseline laboratory data
Warfarin Placebo Warfarin Placebo
(N541) (N544) P
N (%)
Age 58.962.3 57.862.6 NS
Thrombosis 8 (20) 8 (18)Male gender % 56 64 NS
Infection 2 (5) 2 (5)Race %
Maturation of access 13 (32) 17 (39)Caucasian 8 11 NS
Death 1 (2) 1 (2)African American 40 32
One-years duration 3 (7) 7 (16)Hispanic 43 50
Mechanical failure 1 (3) —Other 10 7
Peritoneal dialysis 1 (2) —Etiology of ESRD %
Transplant 3 (7) 1 (5)Diabetes mellitus 49 55
Medical contraindicationHypertension 14 13
Hemorrhage 1 (2) 1 (2)Glomerulonephritis 15 18
Anticoagulation 1 (2) 3 (7)HIV nephropathy 7 9
Extensive surgery 1 (2) —Cholesterol emboli 2 2
Persistently elevated INR/ADPCKD 5 —
without hemorrhage — 1 (2)Scleroderma 2 —
Hepatic failure 1 (2) —Unknown 7 4
Lost to follow-up 4 (10) 1 (2)Aspirin use % 39 52 NS
Accidental TCC removal 2 (5) 1 (2)Baseline INR 1.0760.02 1.0660.02 NS
Baseline Hgb g/dL 9.160.2 10.260.4 0.02 Abbreviations are: TCC, tunneled-cuffed catheter; INR, international normal-
ized ratio.
Plus-minus signs indicate mean 6 SEM. Abbreviations are: HIV, human im-
munodeficiency virus; ADPCKD, autosomal-dominant polycystic kidney disease;
INR, international normalized ratio; Hgb, hemoglobin.
sepsis and one patient who received placebo (aspirin)
who died of a thrombotic cerebral vascular accident.
Table 2. Laboratory data during the study period
Hemorrhagic events occurred in two patients: one receiv-
Warfarin Placebo ing warfarin (no aspirin) who developed cerebral emboli
(N 5 41) (N 5 44) P with peripheral areas of hemorrhage and one in the pla-
Mean INR 1.1660.04 1.1760.03 NS cebo group (no aspirin) with a bleeding decubitus ulcer.
Adjusted mean INR
Mechanical failure occurred in one patient in the warfa-(INR/kg body wt 3 1022) 1.7360.09 1.8460.1 NS
Mean INR .1.00 % 83 82 NS rin group. In this case, the TCC was malpositioned as
Increase in INRa % 963 1163 NS documented by a venogram performed on day 20.
Mean Hgb 10.260.2 10.560.2 NS
Incipient thrombosis, requiring intralumenal throm-Mean Hgb .10.5 g/dL % 42 64 0.04
Increase in Hgba % 1463 763 NS bolysis with UK, occurred in 40 TCCs: 17 out of 41 (42%)
Erythropoietin dose U/kg/HD session 10069 9968 NS in the warfarin group and 23 out of 44 (52%) in the
Intradialytic heparin dose U/kg 3763 3262 NS
placebo group (P 5 NS). Although there were fewerMean monthly URR % 65.261.6 64.261.1 NS
.1 Hospitalizations % 33 27 NS fibrin sheath-stripping procedures in the warfarin group
compared with the placebo group (7 vs. 18%), this wasAbbreviations are: INR, international normalized ratio; Hgb, hemoglobin;
HD, hemodialysis; URR, urea reduction ratio. not a statistically significant finding (P 5 0.14). A totala Baseline to mean intrastudy value
of 16 TCCs, 8 in each group, were removed because of
late malfunction (fibrin sheath formation or thrombus).
All but 1 of the 16 patients whose TCC failures were
due to late malfunction received a dose of intralumenalthe erythropoietin or intradialytic heparin dose, number
UK, in an attempt to salvage the TCC using thromboly-of hospitalizations, mean INR, adjusted mean INR/kg
sis, prior to TCC removal. There was no relationshipbody weight, mean hemoglobin, or the delivered dose of
between TCC loss caused by thrombosis and TCC typedialysis per treatment (as measured by the mean monthly
URR) between the patients receiving warfarin compared or site of insertion.
The findings of a multivariate analysis adjusted forwith placebo. However, a significantly larger percentage
of the placebo group had a mean hemoglobin of greater warfarin, aspirin use, diabetes mellitus, mean hemoglo-
bin, mean INR, and infection are provided in Table 4.than 10.5 g/dL (Table 2). During the study period, there
was an increase in the mean INR and mean hemoglobin There was no significant difference in either TCC loss
caused by late malfunction (thrombosis or fibrin sheathfrom baseline values in both the warfarin and placebo
patients; however, these changes were similar between formation, primary endpoint) or UK requirement (incip-
ient thrombosis, secondary endpoint) between the warfa-the groups.
The reasons for study completion are outlined in Table rin and placebo groups (Fig. 2). Similarly, aspirin use,
race, sex, age, and TCC type had no significant effect3. Two deaths occurred during the study period: one
patient in the warfarin group (no aspirin) who died of on either outcome. In addition, there was no significant
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Table 4. Adjusted relative risks for study endpoints: Late TCC malfunction and intervention with UK
Primary outcome Secondary outcome
TCC failure due to First indication
late malfunction P value for urokinase P value
Warfarin 0.8 (0.3–2.3) 0.63 0.7 (0.4–1.4) 0.38
Aspirin 0.5 (0.2–1.9) 0.32 1.0 (0.5–2.0) 0.92
Diabetes mellitus 3.6 (1.0–13.4) 0.054 2.0 (1.0–4.3) 0.06
Hgb , 10.5 g/dL 5.2 (1.4–18.8) 0.01 2.1 (1.0–4.4) 0.04
INR , 1.00 4.0 (1.1–14.5) 0.04 2.8 (1.3–6.1) 0.009
TCC infection 0.7 (0.2–2.1) 0.52 1.7 (0.9–3.2) 0.11
Data are adjusted relative risk (95%CI). Abbreviations are: INR, international neutralization rate; Hgb, hemoglobin; UK, urokinase; TCC, tunneled-cuffed catheter.
association between the primary or secondary outcomes The mean 6 SEM rate of UK dosing/1000 TCC days
and the following variables: number of hospitalizations, was similar between the groups: warfarin 17.7 6 5.0 versus
erythropoietin dose (U/kg), intradialytic heparin dose placebo 18.1 6 4.7 (P 5 NS). A multivariate analysis was
(U/kg), or serum albumin. performed using linear regression to determine factors
Factors that were significantly associated with an in- associated with the rate of UK dosing. Factors analyzed
creased risk of TCC failure caused by late malfunction were warfarin administration aspirin use, hemoglobin,
(primary end point) were the presence of a mean hemo- INR, sex, age, diabetes, TCC infection, albumin, erythro-
globin ,10.5 g/dL [relative risk (RR) 5 5.2, 95% CI, poietin dose, heparin dose, and hospitalization number/
1.4 to 18.7, P 5 0.013], a mean INR ,1.00 (RR 5 4.0, TCC days survival. Of these, only hemoglobin and INR
95% CI, 1.1 to 14.5, P 5 0.04; Table 4 and Fig. 3). Patients were significantly associated with the rate of UK admin-
with diabetes mellitus also had a higher risk of TCC istration: [hemoglobin (Hgb) .10.5 g/dL: standardized
failure caused by late malfunction; however, this did not b coefficient 5 20.24, P 5 0.02] and INR (INR .1.00:
reach statistical significance (RR 5 3.6, 95% CI, 1.0 to standardized b coefficient 5 20.33, P 5 0.002).
13.4, P 5 0.054). Forty-seven percent of all patients had A separate multivariate analysis (adjusted for mean
a mean hemoglobin ,10.5 g/dL, and 18% had a mean INR, mean hemoglobin, diabetes mellitus, and infection)
INR of ,1.00. was performed comparing patients receiving both warfa-
The same three factors were also associated with an rin and aspirin with patients not receiving either drug.
increased risk of incipient thrombosis (secondary end There was no significant difference in the primary or
point): a mean hemoglobin ,10.5 g/dL (RR 5 2.1, 95% secondary outcomes between the groups.
CI, 1.0 to 4.4, P 5 0.04), a mean INR ,1.00 (RR 5 2.8, Sixty percent of patients with at least one TCC-associ-
95% CI, 1.3 to 6.1, P 5 0.009), and diabetes mellitus ated infection required UK compared with only 40% of
(RR 5 2.0, 95% CI, 1.0 to 4.3, P 5 0.06; Table 4). those who never had a TCC-associated infection (P 5
Diabetes mellitus was less prevalent in the male popula- 0.054). However, the rate of UK dosing/1000 TCC days
tion (43% male vs. 65% female, P 5 0.051) and was was not significantly associated with TCC infection, and
equally prevalent with respect to race. There were no nor were the primary (late TCC malfunction) or second-
significant differences between men and women with ary (incipient TCC thrombosis) outcomes.
regard to mean INR, mean hemoglobin, age, warfarin
randomization, or aspirin use. There was no significant
DISCUSSIONrelationship between the INR during the study period
Late TCC malfunction in a previously functioningand the presence of one or more TCC-associated infec-
catheter is usually due to thrombosis or fibrin sheathtions, the number of hospitalizations/TCC days survival,
formation. In one series of 163 episodes of TCC malfunc-serum albumin, or the intradialytic heparin dose.
tion, 121 (74.2%) episodes corrected with thrombolyticA multivariate analysis was performed using linear
therapy using UK and 38 (23.3%) were due to the pres-regression to determine factors associated with the mean
ence of a fibrin sheath [5]. In combination, thrombus orhemoglobin. The variables analyzed were mean INR,
fibrin sheath formation accounted for 97.5% of late TCCalbumin, sex, warfarin randomization, aspirin use, diabe-
malfunction. Although venography and ultrasound havetes mellitus, TCC-infection, heparin dose, erythropoietin
been used in similar trials, the interpretation of thesedose, and the number of hospitalizations/TCC days sur-
imaging studies for the presence of a fibrin sheath is veryvival. Factors that significantly correlated with the mean
difficult [14]. There is often marked variability in thehemoglobin value were aspirin use (standardized b coef-
appearance of the contrast injection pattern due to eitherficient 5 0.37, P 5 0.001) and the erythropoietin dose
(standardized b coefficient 5 20.31, P 5 0.003). the incomplete nature of the fibrin sheath or due to
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Fig. 3. Thrombosis-free TCC survival according to the (A) mean INRFig. 2. (A) Thrombosis-free tunneled cuffed catheter (TCC) survival
and the (B) mean serum hemoglobin concentration. The analyses werecomparing warfarin (dashed line) versus placebo (solid line). (B) Uroki-
performed using Cox regression, adjusted for aspirin use, warfarin ad-nase-free TCC survival comparing warfarin (dashed line) versus placebo
ministration, INR, hemoglobin, diabetes, sex, and TCC infection.(solid line). The analyses were performed using Cox regression, adjusted
for aspirin use, hemoglobin, international normalized ratio (INR), dia-
betes, sex, and TCC infection.
primary and secondary clinically determined endpoints
of this study are reliable indicators of late TCC malfunc-
repeated flushing, which creates defects in the fibrin tion, with a high probability of the presence of a TCC
sheath that allow contrast infusion. In fact, in one series, thrombus or fibrin sheath.
the fibrin sheath was only visualized upon injection of Fixed minidose warfarin (1 mg/day) was ineffective in
contrast during removal of the catheter [15]. Ultrasound preventing late TCC malfunction (fibrin sheath/throm-
has not been validated for the diagnosis of fibrin sheath bus formation) or in reducing the requirements for intra-
formation and may be as problematic, as other conven- catheter thrombolytic therapy (UK) in HD patients.
tional cross-sectional imaging studies, such as computer However, the presence of an elevated INR does appear
axial tomography, often fail to depict the fibrin sheath to be significantly associated with a 75 and 50% reduction
due to its relatively diffuse and thin encasement of cathe- in risk of these thrombotic end points, respectively. In
ters [14]. In a recent review of the management of fibrin addition, there was an inverse association between the
sheaths, Crain recommended that TCC venogram be INR and the rate of UK dosing. These data support the
deferred when an appropriate history, of previously ade- need for a clinical trial of conventional adjusted-dose
quate TCC blood flow suggested fibrin sheath formation warfarin (aiming for an INR of 2.0 to 3.0) in TCCs used
for HD. The mean INR increased from baseline by ap-[14]. Based on these data and recommendations, the
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proximately 10% in patients receiving both warfarin and for the prevention of late TCC malfunction because of
thrombosis or fibrin sheath formation in HD TCCs.placebo. One explanation for this is improper “heparin-
washout” technique for blood sampling; however, the However, because of the fact that the presence of a
higher INR was associated with a reduced risk of TCCrise in the INR occurred gradually and was not observed
with the first TCC-drawn values. Alternatively, antibiotic thrombosis, a study using adjusted-dose warfarin (target
INR 2.0 to 3.0) is necessary. The results of this studyuse or malnutrition may be associated with alterations in
the INR. However, there was no significant relationship do not exclude the possibility that higher dose warfarin
therapy, tailored to achieve a therapeutic INR, maybetween the INR during the study period and the pres-
ence of one or more TCC-associated infections, the num- prove beneficial in preventing TCC thrombosis. How-
ever, a randomized clinical trial is necessary, document-ber of hospitalizations, serum albumin, or the intradia-
lytic heparin dose. ing the proven benefit and safety of anticoagulation,
before therapeutic warfarin can be recommended forAnemia was associated with a significantly higher risk
of TCC thrombosis. This finding seems somewhat para- routine clinical use.
doxical; in fact, previous studies report an increased risk
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